- Home
- BOX vs RYTM Comparison
BOX vs RYTM Comparison
Compare BOX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOX
- RYTM
- Stock Information
- Founded
- BOX 2005
- RYTM 2008
- Country
- BOX United States
- RYTM United States
- Employees
- BOX N/A
- RYTM N/A
- Industry
- BOX Computer Software: Prepackaged Software
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BOX Technology
- RYTM Health Care
- Exchange
- BOX Nasdaq
- RYTM Nasdaq
- Market Cap
- BOX 4.4B
- RYTM 3.8B
- IPO Year
- BOX 2015
- RYTM 2017
- Fundamental
- Price
- BOX $37.79
- RYTM $61.33
- Analyst Decision
- BOX Strong Buy
- RYTM Strong Buy
- Analyst Count
- BOX 10
- RYTM 12
- Target Price
- BOX $37.40
- RYTM $76.75
- AVG Volume (30 Days)
- BOX 2.9M
- RYTM 632.6K
- Earning Date
- BOX 05-27-2025
- RYTM 05-07-2025
- Dividend Yield
- BOX N/A
- RYTM N/A
- EPS Growth
- BOX 77.37
- RYTM N/A
- EPS
- BOX 1.30
- RYTM N/A
- Revenue
- BOX $1,101,744,000.00
- RYTM $136,863,000.00
- Revenue This Year
- BOX $7.14
- RYTM $37.88
- Revenue Next Year
- BOX $7.11
- RYTM $72.84
- P/E Ratio
- BOX $29.13
- RYTM N/A
- Revenue Growth
- BOX 4.88
- RYTM 48.88
- 52 Week Low
- BOX $24.63
- RYTM $35.35
- 52 Week High
- BOX $37.96
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- BOX 82.41
- RYTM 51.78
- Support Level
- BOX $30.97
- RYTM $58.72
- Resistance Level
- BOX $37.66
- RYTM $63.24
- Average True Range (ATR)
- BOX 0.72
- RYTM 2.43
- MACD
- BOX 0.65
- RYTM -0.15
- Stochastic Oscillator
- BOX 97.57
- RYTM 65.51
About BOX Box Inc.
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file-sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature to enhance workflow management and collaboration.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.